LIPTIDE
Live / Registered — Registered (as of 28 Apr 2020)
What this means for you
Registered since 28 Apr 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79243223
- Registration number
- 6039104
- Mark type
- Stylized text
- Filed
- 30 Jul 2018
- Published for opposition
- 11 Feb 2020
- Registered
- 28 Apr 2020
- Attorney of record
- Thomas W. Cole
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; chemicals for pharmaceutical use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations being nanoparticles for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing siRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing RNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing shRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing mRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing DNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; drug delivery agents being made from lipids, liposomes or peptides in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; pharmaceuticals and pharmaceutical preparations containing lipids, liposomes or peptides for treatments in the form of gene therapy used in the treatment of cancer; drug delivery agents in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations in the form of nanoparticles; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; pharmaceutical and drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material in the form of nanoparticles; preparations for detecting genetic predispositions for medical purposes; pharmaceuticals and pharmaceutical preparations for use in gene therapy in the form of nanoparticles used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; drug delivery agents for use in gene therapy in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents being nanoparticles in the form of an artificial virus that facilitate the delivery of a wide variety of pharmaceuticals; pharmaceutical and natural remedies for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; medical preparations for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; biochemical preparation for medical purposes for treatments in the form of gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; biological preparations for medical purposes for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; reagents for medical use; reagents for use in medical genetic testing; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics for use in the treatment of cancer; pharmaceutical preparations for use in chemotherapy for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment and prevention of tumours
Owner
- Nanogenics Limited, London, GB
- Nanogenics Limited, London, GB
- Nanogenics Limited, London, GB
Prosecution history
- 28 Apr 2025 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 19 Apr 2024 — NEW REPRESENTATIVE AT IB RECEIVED
- 26 Sept 2020 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 08 Sept 2020 — FINAL DISPOSITION NOTICE SENT TO IB
- 05 Sept 2020 — FINAL DISPOSITION PROCESSED
- 28 Jul 2020 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 28 Apr 2020 — REGISTERED-PRINCIPAL REGISTER
- 03 Apr 2020 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 18 Mar 2020 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 18 Mar 2020 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 11 Feb 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Feb 2020 — PUBLISHED FOR OPPOSITION
- 07 Feb 2020 — NOTIFICATION PROCESSED BY IB
- 22 Jan 2020 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 22 Jan 2020 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB